1 |
Volzke H, Robinson DM, Schminke U, Ludemann J, Rettig R, Felix SB, et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab 2004;89(4):2145-9.
DOI
|
2 |
Dorr M, Empen K, Robinson DM, Wallaschofski H, Felix SB, Volzke H. The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. Eur J Endocrinol 2008;159(2):145-52.
DOI
|
3 |
Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4mIU/l: a prospective study. Clin Endocrinol (Oxf) 2010;72(5):685-8.
DOI
|
4 |
Rosario PW. The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol (Oxf) 2008;68(3):491-2.
DOI
|
5 |
Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011;96(1):E1-8.
DOI
|
6 |
Donangelo I, Suh SY. Subclinical Hyperthyroidism: When to Consider Treatment. Am Fam Physician 2017;95(11):710-6.
|
7 |
Cooper DS. The side effects of antithyroid drugs. Endocrinologist 1999;9(6):457-76.
DOI
|
8 |
Park KH, Lee EJ. Recent review on medical treatment of thyroid disease. J Korean Med Assoc 2012;55(12):1207-14.
DOI
|
9 |
Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291(2):228-38.
DOI
|
10 |
Kim YA, Park YJ. Prevalence and risk factors of subclinical thyroid disease. Endocrinol Metab (Seoul) 2014;29(1):20-9.
DOI
|
11 |
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87(2):489-99.
DOI
|
12 |
Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000; 53(6):733-7.
DOI
|
13 |
Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012;379(9821):1142-54.
DOI
|
14 |
Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, et al. Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005. Eur J Endocrinol 2008; 158(6):823-7.
DOI
|
15 |
Ko KD. Subclinical Thyroid Dysfunction in the Elderly. J Korean Geriatr Soc 2014;18(3):111-21.
DOI
|
16 |
Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005;152(1):1-9.
DOI
|
17 |
Schlote B, Schaaf L, Schmidt R, Pohl T, Vardarli I, Schiebeler H, et al. Mental and physical state in subclinical hyperthyroidism: investigations in a normal working population. Biol Psychiatry 1992;32(1):48-56.
DOI
|
18 |
Ahn SY, Ahn YM, Lee BC, Lee UJ, Song BK, Jung JC, et al. Kidney Internal medicine Committee of Korean Medicine. Nephro-Endo System in Internal Medicine of Korean Medicine. 2nd edition. Seoul: Koonja publishing company; 2015, p. 89-90, 282-4.
|
19 |
Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001;142(5):838-42.
DOI
|
20 |
Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000;85(12):4701-5.
DOI
|
21 |
Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf) 2006; 64(3):323-9.
DOI
|